GRI Bio Strengthens Global Patent Holdings for NKT Therapies
GRI Bio Expands Intellectual Property with Global Patent Grants
GRI Bio, Inc. is taking significant strides towards strengthening its intellectual property (IP) portfolio with the recent granting of two global patents. This progression highlights the company’s unwavering commitment to developing its innovative pipeline of Natural Killer T (NKT) cell modulators targeted at addressing inflammatory, fibrotic, and autoimmune diseases.
Details of the Granted Patents
The two notable patents recently granted encompass:
European Patent on NKT Cell Modulators
The European patent application No. 19,166,502 is titled “Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.” This patent secures rights for GRI-0803, an innovative activator of human type 2 diverse NKT (dNKT) cells, aimed at improving treatment options for autoimmune disorders. An early focus for this development is systemic lupus erythematosus (SLE). The mechanism involves the activation of dNKT cells to inhibit type 1 invariant NKT (iNKT) cell activity mediated by dendritic cells.
Japanese Patent for Inflammatory Conditions
Meanwhile, Japanese patent application No. 2023-000750 titled “Prevention and Treatment of Inflammatory Conditions” covers the methodologies and compositions for effectively modulating dNKT and/or iNKT cells. This ensures robust protective measures and therapies against inflammatory, fibrotic, and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist which effectively inhibits iNKT cells in patients.
Comments from GRI Bio Leadership
Marc Hertz, PhD and CEO of GRI Bio, expressed, “The granting of these patents marks yet another milestone in our mission to expand our global patent estate. Our commitment to enhancing our IP portfolio underscores the strategic importance of our innovative NKT cell modulators and our extensive library of over 500 proprietary compounds.” This dedication reflects a powerful opportunity to effectively address unfulfilled medical needs associated with inflammatory and autoimmune diseases.
Current Development Initiatives
GRI Bio continues to develop its lead program, GRI-0621, which is currently in a Phase 2a clinical trial. This randomized, double-blind, multi-center, placebo-controlled study aims to evaluate the treatment of idiopathic pulmonary fibrosis (IPF). The initial results of the Phase 2a biomarker study are anticipated soon, with topline results expected shortly thereafter. Ongoing trials are crucial as GRI Bio endeavors to provide new solutions for patients grappling with IPF, a chronic and serious lung disease that necessitates advanced treatment approaches.
About GRI Bio, Inc.
GRI Bio, Inc. operates within the biopharmaceutical sector, focusing on revolutionary approaches to treating debilitating inflammatory, fibrotic, and autoimmune diseases. The company's therapeutic strategies revolve around targeting the activity of NKT cells, which are pivotal in regulating the inflammatory cascade. By effectively interrupting the progression of disease and aiming to restore immune balance, GRI Bio's approach presents a promising avenue for patient care. The significance of NKT cells as a vital link between innate and adaptive immune responses further emphasizes the company's commitment to innovative solutions. GRI Bio’s lead program, GRI-0621, serves as a groundbreaking oral therapeutic target against iNKT cell activity, specifically for IPF treatment. In addition to this, the company is progressing with a range of dNKT agonists aimed at systemic lupus erythematosus treatment.
Frequently Asked Questions
What are the newly granted patents from GRI Bio?
GRI Bio has obtained patents in Europe and Japan focused on NKT cell modulators aimed at treating autoimmune and inflammatory diseases.
How does GRI Bio's lead program function?
GRI-0621, GRI Bio's lead program, aims to inhibit iNKT cell activity to treat idiopathic pulmonary fibrosis and restore immune balance.
What diseases does GRI Bio target?
The company targets inflammatory, fibrotic, and autoimmune diseases through its innovative NKT cell modulators.
Who is the CEO of GRI Bio?
Marc Hertz, PhD, is the Chief Executive Officer of GRI Bio.
How can I contact GRI Bio for investor inquiries?
Investor inquiries can be directed to the JTC Team, LLC, specifically to Jenene Thomas at (908) 824-0775 or via email at GRI@jtcir.com.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.